CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
about
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewDiagnostic, prognostic and therapeutic role of CD30 in lymphoma.Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age.Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 casesNew uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.Epstein-Barr virus-positive follicular lymphoma.Treatment approaches of hard-to-treat non-Hodgkin lymphomas.Cytologic perspectives on neoteric B-cell lymphoproliferative disorders.Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.Age and cellular composition influence overall survival in a collective of non-immunocompromised patients with EBV-positive diffuse large B-cell lymphoma from a German lymphoma center.CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma.Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.Is CD30 a predictive biomarker for brentuximab vedotin?Brentuximab vedotin: clinical updates and practical guidance.A treatment refractory CD30-positive diffuse large B cell lymphoma in the ileal neobladder.Different prevalence and clinical outcome of Epstein-Barr virus positive diffuse large B-cell lymphoma between North American and non-Western populations.Targeting CD30 expression in diverse Large B-cell lymphoma entitiesSpanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma
P2860
Q27304386-EBC6133C-2CCC-4B63-9A9E-1AA7C961A3A8Q30240160-A51B2232-BD86-4A50-904C-0444F7F64243Q35880791-44B6569C-444A-41E8-ACBB-7F2F7A94BA12Q36511738-C8529D95-C15B-4DF1-90A8-D6E5CFA25B5EQ38896683-A469FE1D-A1D2-4B70-9C91-35177A43A098Q38950501-A7F185A7-A73A-42D9-A8E3-CD79D21A0972Q39041047-90D13502-D9A4-4705-B7D8-07F1468CCE80Q39091822-7C118F00-8E4A-4DDA-8C9A-70440190F883Q39359287-04B482E4-1913-4707-8F30-4C7B0CCE5297Q40422243-5D22F9AB-FD57-481B-9E4C-DBACC1EA1F9EQ40696036-1BACD1E3-3A19-448A-9E5E-2520A449D38DQ41411254-925341E6-A3DC-4912-BAF2-99D56F57691EQ47143718-4BD7D002-376C-409C-9124-749132A60586Q47424027-39DDA068-B8B3-4734-A41C-91BC3769E2B9Q47584171-8E14A946-133C-4086-B083-07B2C15E18A5Q49282959-B104D767-B75C-4335-B52E-725962ACDEE8Q50220287-222D732E-01C7-45AC-A294-1D5C0236C42DQ55710335-E56CB3E4-E8B3-4F00-AD3A-C23CAB5D096AQ58011053-E5BE55DA-85F1-460E-AD64-C19B28655F8AQ58767936-31F59827-6D9C-4DE9-873C-1F7ADED17AE8
P2860
CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
CD30 expression in de novo dif ...... d study from British Columbia.
@en
CD30 expression in de novo dif ...... d study from British Columbia.
@nl
type
label
CD30 expression in de novo dif ...... d study from British Columbia.
@en
CD30 expression in de novo dif ...... d study from British Columbia.
@nl
prefLabel
CD30 expression in de novo dif ...... d study from British Columbia.
@en
CD30 expression in de novo dif ...... d study from British Columbia.
@nl
P2093
P2860
P356
P1476
CD30 expression in de novo dif ...... d study from British Columbia.
@en
P2093
Christian Steidl
Graham W Slack
Laurie H Sehn
P2860
P304
P356
10.1111/BJH.13085
P407
P577
2014-08-19T00:00:00Z